MarginsXMarginsX
Home › Markets › Health Care › SERA

Sera Prognostics Inc. (SERA)

SERA trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.94
-3.48% on the day
Market cap
$77.2M
Micro cap
Revenue · 2025
$81K
+5.2% on 2024
Net income · 2025
-$31.9M
-39417.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/0001534969-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSERA on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryUnited States
IPO year2021
SEC CIK0001534969
SEC industry codeServices-Medical Laboratories
Incorporated inDE

Financials · 2025

LineValue
Revenue$81K
Net income-$31.9M
Operating income-$36.5M
Net margin-39417.3%
Operating margin-45066.7%
Revenue growth+5.2%
Cash$3.9M
Total assets$101.9M
P/E (computed)Net income was not positive
P/S (computed)952.5×

Warning signs

Cash runway
1.7 months
$4.0M cash at September 30, 2026
Share count, 1 year
+3.0%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$650K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$4.0M cash; operating cash flow -$7.1M a quarter.Report 2026-09-30
Shares outstanding39,769,839 (2026-10-30); 38,594,793 a year earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Salt Lake City, Utah, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $650K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$42K-$8.1M-$7.3M$4.0MNo debt tags$96K10-Q 2026-11-04
Q2 2026
2026-06-30
$30K-$9.1M-$6.3M$4.4MNo debt tags$70K10-Q 2026-08-12
Q1 2026
2026-03-31
$14K-$8.4M-$8.8M$4.2MNo debt tags$57K10-Q 2026-05-06
Q4 2025
2025-12-31
$10K-$7.9M-$6.1M$3.9MNo debt tags$81K10-K 2026-03-18
Q3 2025
2025-09-30
$16K-$7.8M-$6.5M$4.1MNo debt tags$95K10-Q 2025-11-13
Q2 2025
2025-06-30
$17K-$8.0M-$5.5M$5.0MNo debt tags$108K10-Q 2026-08-12
Q1 2025
2025-03-31
$38K-$8.2M-$7.6M$5.2MNo debt tags$115K10-Q 2026-05-06
Q4 2024
2024-12-31
$24K-$8.6M-$6.3M$4.0MNo debt tags$77K10-K 2026-03-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-18
Latest annual report10-K2026-03-18
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-06-01

Source: SEC EDGAR submissions feed, 660 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.2%
1 month-1.5%
3 months0.0%
Year to date-31.9%
1 year-31.9%
From 52-week high-45.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
XGNExagen Inc.$3.77-8.72%$96.2M
BDSXBiodesix Inc.$9.00-8.91%$99.8M
KEQUKewaunee Scientific Corporation$35.05-1.81%$101.5M
BNRBurning Rock Biotech Limited$12.74-4.43%$134.4M
TLSITriSalus Life Sciences Inc.$2.27-6.58%$140.1M
YDESYD Bio Limited$4.83-1.02%$342.1M
MDXHMDxHealth SA$0.1490+3.40%$14.2M
FLGTFulgent Genetics Inc.$24.07-2.37%$672.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier